Generic POLYMYXIN B SULFATE INN entry, drug patent expiration information and freedom to operate

Sponsor	Phase
Madonna Magdy Fahmy	Early Phase 1
University of Miami	N/A
Bascom Palmer Eye Institute	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xellia Pharms Aps	POLYMYXIN B SULFATE	polymyxin b sulfate	INJECTABLE;INJECTION	202766-001	Jan 15, 2014	AP	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline	AEROSPORIN	polymyxin b sulfate	INJECTABLE;INJECTION	062036-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Epic Pharma Llc	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	065006-001	Dec 17, 1998	AT	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: March 19, 2026

What Are the Key Drivers of Polymyxin B Sulfate Demand?

Polymyxin B sulfate is an antibiotic primarily used for multidrug-resistant Gram-negative bacterial infections. Its market is influenced by rising antimicrobial resistance, regulatory approvals, and manufacturing trends.

Factors boosting demand

Antimicrobial resistance (AMR): Increased resistance to carbapenems and other antibiotics has elevated the reliance on polymyxins, including Polymyxin B. The WHO classifies carbapenem-resistant Enterobacteriaceae as critical priority pathogens.
Infections in healthcare settings: Rising multidrug-resistant infections in hospitals, especially in ICU environments, heighten the need for potent antibiotics like Polymyxin B.
Limited alternatives: Few antibiotics reliably target certain resistant Gram-negative bacteria, maintaining Polymyxin B's importance.

Constraints on demand

Toxicity concerns: Nephrotoxicity and neurotoxicity limit widespread use, leading clinicians to reserve the drug for severe cases.
Regulatory restrictions: US FDA and EMA approvals vary; in some markets, use is off-label or restricted.

What Are the Main Market Players and Supply Trends?

Major pharmaceutical companies actively manufacture Polymyxin B sulfate, predominantly in India and China, which are primary exporting hubs.

Key manufacturers

X-Gen Pharmaceuticals (India): Massively involved in bulk production.
Hikma Pharmaceuticals (UK): Offers Polymyxin B formulations.
Wuxi Biologics (China): Supplies bulk API manufacturing capabilities.

Supply chain considerations

API production is concentrated in India and China, leading to supply risks due to geopolitical issues, factory disruptions, or regulatory changes.
The global shortage impacted availability in 2019-2020 but has since stabilized with increased manufacturing capacity.

How Do Regulatory Policies Shape Market Trajectory?

Regulatory landscapes directly influence market size and growth endpoints.

Major regulatory developments

FDA approval in the US: In 2019, the FDA approved newly marketed Polymyxin B formulations, improving clarity around dosing and administration.
EMA approvals: Regulatory frameworks are more restrictive, with use limited primarily to hospital settings.

Impact on commercial opportunities

The approval of fixed-dose combinations and brand-name products fosters market expansion.
Stringent regulations on toxicity influence clinician prescribing patterns, possibly limiting market size.

What Is the Financial Outlook for Polymyxin B Sulfate?

Revenue estimates and growth projections

The global polymyxin market, including Polymyxin B and colistin, reached approximately USD 200 million in 2021.
Polymyxin B is estimated to account for around 55% of this figure, with a compound annual growth rate (CAGR) of approximately 10% through 2027 [2].

Market segmentation

Segment	Share (2021)	CAGR (2022-2027)
Hospital procurement	70%	12%
Direct exports (API)	30%	8%

Hospital procurement dominates due to use in severe, resistant infections.

Pricing trends

Unit prices for Polymyxin B API have increased slightly owing to raw material costs and regulatory compliance expenses.
Formulation prices reflect manufacturing costs and regional pricing policies.

How Do Future Trends Influence Financial Outcomes?

Growing antimicrobial resistance: Will likely sustain or increase demand.
New formulations or combination therapies: Could expand clinical use, positively affecting sales.
Emerging resistance to polymyxins: May limit long-term growth or necessitate new drugs.
Regulatory developments: Stricter use protocols might affect demand volumes.

Summarized Key Points

AMR has driven heightened use of Polymyxin B, primarily in hospital settings targeting multidrug-resistant infections.
The manufacturing market is concentrated in India and China, with supply chain and geopolitical risks.
Regulatory developments, especially in the US and Europe, shape market expansion and product approvals.
The market is projected to grow at a CAGR of approximately 10% through 2027, driven by increasing resistance and limited alternatives.
Pricing remains influenced by raw material costs and regional policies, with potential upward pressure due to regulatory compliance.

Key Takeaways

Polymyxin B sulfate faces demand expansion primarily from AMR-driven hospital use.
Production is geographically concentrated, which may introduce supply risks.
Market growth hinges on resistance patterns, regulatory approvals, and emerging clinical data.
Pricing trends reflect manufacturing costs and regional regulatory environments.
Long-term viability depends on microbial resistance evolution and potential for new therapies.

FAQs

1. What factors limit the global expansion of Polymyxin B sulfate?
Nephrotoxicity and neurotoxicity restrict usage to severe infections, and regulatory policies in different regions limit off-label uses.

2. How does antimicrobial resistance impact Polymyxin B market prospects?
AMR increases demand due to limited alternatives for resistant Gram-negative bacteria but may also prompt reduced use if resistance to polymyxins develops.

3. Which regions dominate the Polymyxin B sulfate market?
India and China dominate API manufacturing and export; North America and Europe are primarily end-user markets with hospital procurement.

4. What are the primary regulatory considerations for Polymyxin B?
FDA approvals in the US clarify dosing and safety profiles; EMA regulations are more restrictive, influencing market entry and use.

5. How might emerging therapies affect the future market?
Development of new antibiotics or adjunct therapies targeting resistant bacteria could reduce reliance on Polymyxin B, impacting market growth.

References

[1] World Health Organization. (2017). Critically important antimicrobials for human medicine. 5th revision.
[2] MarketsandMarkets. (2022). Polymyxin market by type, application, and region.

US Patents:	0
Tradenames:	5
Applicants:	15
NDAs:	15
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	6
What excipients (inactive ingredients) are in polymyxin b sulfate?	polymyxin b sulfate excipients list
DailyMed Link:	polymyxin b sulfate at DailyMed

Polymyxin b sulfate - Generic Drug Details

What are the generic drug sources for polymyxin b sulfate and what is the scope of freedom to operate?

Summary for polymyxin b sulfate

Recent Clinical Trials for polymyxin b sulfate

Pharmacology for polymyxin b sulfate

Medical Subject Heading (MeSH) Categories for polymyxin b sulfate

Anatomical Therapeutic Chemical (ATC) Classes for polymyxin b sulfate

US Patents and Regulatory Information for polymyxin b sulfate

Market Dynamics and Financial Trajectory for Polymyxin B Sulfate